Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Summit Therapeutics Inc. seeks a Director, Value Outcomes Liaison (VOL) to lead engagement with US payer and decision-maker stakeholders for ivonescimab. You will educate on clinical and economic value, support formulary access, and collaborate to enhance patient outcomes through robust HEOR evidence.
The role requires deep health economics expertise, oncology knowledge, and ability to drive cross-functional strategies with medical affairs and market access teams. Significant travel is expected.
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:
Non-small Cell Lung Cancer (NSCLC)
HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview:
Summit Therapeutics is seeking a Director, Value Outcomes Liaison (VOL), to join our mission of developing Ivonescimab, a novel and unique immunotherapy with the potential to help patients suffering from life-threatening cancers.
The Director, VOL is a critical member of an expanding team, responsible for interfacing with US population-based decision makers (PBDMs) including payers, health systems, clinical pathway organizations, P&T committees, and policy makers. The VOL educates key stakeholders on clinical, economic, and humanistic impact of ivonescimab to help inform formulary access, pathway/guideline decisions, and improve lives of cancer patients. Providing objective and scientifically sound medical information on ivonescimab and the relevant disease states through use of economic models, outcomes tools, educational programs, and collaborations to enhance key stakeholder recognition of Summit Therapeutics. The VOL will compliantly partner with the commercial market access field team to facilitate access to ivonescimab through proactive engagement with organized customers, ensuring the delivery of accurate, non-promotional medical information.
Roles and responsibilities:
Experience/Education:
This is the pay for this position
Pay Transparency
$190,000 - $237,000 USD
Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.
Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.
Summit Therapeutics Inc.is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.
Create a Job Alert
Interested in building your career at Summit Therapeutics? Get future opportunities sent straight to your email.
Accepted file types: pdf, doc, docx, txt, rtf
Enter manually
Accepted file types: pdf, doc, docx, txt, rtf
Education
School Select...
Degree Select...
Select...
End date year
Are you located in one of the follow states?New York, Massachusetts, District of Columbia, Maryland * Select...
LinkedIn Profile
Website
Location: (City & State) *
Are you legally authorized to work in your primary country of residence? * Select...
Will you require visa sponsorship now or in the future? * Select...
Are you a current or former employee of PwC? * Select...
CERTIFICATION OF ACCURACY: By submitting this application, I certify that all information provided by me (including any resumes, supporting materials, and responses) is true, complete, and accurate to the best of my knowledge. I understand that any misrepresentation, omission, or falsification of information may result in disqualification from consideration or, if employed, termination of employment.Please certify by typing your legal name in the open text box below. *
For government reporting purposes, we ask candidates to respond to the below self-identification survey.Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiringprocess or thereafter. Any information that you do provide will be recorded and maintained in aconfidential file.
As set forth in Summit Therapeutics’s Equal Employment Opportunity policy,we do not discriminate on the basis of any protected group status under any applicable law.
If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection.As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measurethe effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categoriesis as follows:
A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.
A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.
An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.
An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.